Entera Bio (NASDAQ:ENTX) Shares Gap Up – Should You Buy?

Entera Bio Ltd. (NASDAQ:ENTX) shares gapped up before the market opened on Friday . The stock had previously closed at $3.03, but opened at $3.14. Entera Bio shares last traded at $2.9850, with a volume of 42,396 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ENTX shares. Wall Street Zen upgraded Entera Bio to a “sell” rating in a research report on Saturday, August 8th. Leerink Partners assumed coverage on shares of Entera Bio in a research note on Friday. They issued an “outperform” rating and a $9.00 target price on the stock. UBS Group set a $9.00 price target on shares of Entera Bio in a research report on Friday. HC Wainwright reaffirmed a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $9.00.

Entera Bio Trading Down 3.3%

The company has a market capitalization of $509.32 million, a P/E ratio of -8.37 and a beta of 1.38. The firm has a fifty day moving average of $2.77 and a 200 day moving average of $1.81.

Entera Bio (NASDAQ:ENTX) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06).

Hedge Funds Weigh In On Entera Bio

A hedge fund recently raised its stake in Entera Bio stock. Renaissance Technologies LLC raised its stake in Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 473,442 shares of the company’s stock after buying an additional 365,441 shares during the period. Renaissance Technologies LLC owned about 0.96% of Entera Bio worth $526,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 14.11% of the stock is currently owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.